Pluta Ryszard, Ułamek-Kozioł Marzena
Laboratory of Ischemic and Neurodegenerative Brain Research, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
Drugs available on the market for the treatment of Alzheimer’s disease show only low symptomatic efficacy and phase 3 clinical trials against amyloid have been negative over the past 20 years. As dysfunctional tau protein is more closely correlated with dementia than amyloid, targeting tau protein may be more effective in improving cognitive function in cases of Alzheimer’s disease. It should be emphasized that the development of tau protein therapy is in many ways more complicated than the development of anti-amyloid therapy. Several antibodies to the tau protein and two vaccines are currently undergoing clinical trials. Relatively speaking, tau protein therapy for Alzheimer’s disease is still in its infancy. The purpose of this chapter is to draw the readers’ attention to the various uncertainties and barriers to the success of tau protein therapy in treating Alzheimer’s disease, and to show how future research and clinical trials can avoid previous limitations or mistakes.
市场上可用于治疗阿尔茨海默病的药物仅显示出较低的对症疗效，并且在过去20年中针对淀粉样蛋白的3期临床试验均为阴性。由于功能失调的tau蛋白比淀粉样蛋白与痴呆症的相关性更强，因此针对tau蛋白可能在改善阿尔茨海默病患者的认知功能方面更有效。应该强调的是，tau蛋白疗法的开发在许多方面比抗淀粉样蛋白疗法的开发更为复杂。目前有几种针对tau蛋白的抗体和两种疫苗正在进行临床试验。相对而言，用于治疗阿尔茨海默病的tau蛋白疗法仍处于起步阶段。本章的目的是引起读者对tau蛋白疗法成功治疗阿尔茨海默病所面临的各种不确定性和障碍的关注，并展示未来的研究和临床试验如何避免以前的局限性或错误。
